ANTH will be signing a deal with a partner fairly soon. Actually the earlier the better. They don't want the stock to drift too far below a buck.
The deal should be structured to have a decent upfront payment but not too heavily weighted. It would be better to have the partner pay much of the development costs and to have them take an equity interest in ANTH. If they get the partner to buy 10 million shares at $5/share, the stock will respond accordingly and we will be out of the doldrums. This would allow ANTH to raise funds on its own in the future at $5 or greater ... rather than this $1/share stuff.
When small biotechs look for partners to advance their drugs through clinical trials and to bring them to market, they often strike deals that require upfront payments and milestone payments as the drug moves through clinical trials and government approvals. Anthera could ask the partner to give it, for example, $50 million dollars for the rights to sell their lupus drug outside the USA or in the USA and elsewhere. It could also ask for reimbursement of 50% of the clinical trial/approval costs. And it could ask for milestone payments of $25 million upon FDA or EU approval.
Now rather than just simply pay $50 million to ANTH for future marketing rights to the drug, ANTH could instead give them 10 million shares for the $50 million. Although this results in some dilution, it has the net result of driving the stock price higher, which is good for ANTH in the event that they need to raise money in the future through an equity offering. It also benefits the shareholders of ANTH,of which management is.